Literature DB >> 1510481

[Polycythemia as the first and only manifestation of renal adenocarcinoma].

S Napal Lecumberri1, J I Pascual Piedrola, A Solchaga Martínez, J L Arrondo Arrondo, A Ipiens Aznar.   

Abstract

We report on a 40-year-old patient with adenocarcinoma of the right kidney whose first and only manifestation was the erythrocytosis that had been detected on routine analytical work up. The diagnostic methods (US, IVP, CT, aspiration biopsy cytology and renal arteriography) and treatment (right nephrectomy via extended thoracophrenolaparotomy incision at the level of the ninth rib) are briefly described. The polycythemia remitted following nephrectomy. The etiopathogenesis and hypotheses that have been put forward relative to polycythemia in renal adenocarcinoma are briefly discussed. Renal tumor, particularly renal adenocarcinoma, should be suspected in the presence of polycythemia of unknown origin. Persistent or recurrent polycythemia should prompt us to suspect incomplete tumor excision or metastasis. Surgical risks (embolism, hemorrhage, etc.) may be reduced if hematocrit levels are brought down to within normal levels by bleeding.

Entities:  

Mesh:

Year:  1992        PMID: 1510481

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  2 in total

1.  Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.

Authors:  Daniel M Moreira; Boris Gershman; Christine M Lohse; Stephen A Boorjian; John C Cheville; Bradley C Leibovich; Robert Houston Thompson
Journal:  World J Urol       Date:  2016-02-25       Impact factor: 4.226

2.  Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.

Authors:  Ryan Sun; Rodney H Breau; Ranjeeta Mallick; Simon Tanguay; Frederic Pouliot; Anil Kapoor; Luke T Lavallée; Antonio Finelli; Alan I So; Ricardo A Rendon; Adrian S Fairey; Jean-Baptiste Lattouf; Jun Kawakami; Bimal Bhindi; Naveen S Basappa; Lori A Wood; Georg A Bjarnason; Daniel Y C Heng; Rahul K Bansal
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.